Literature DB >> 12111129

Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus.

Naoya Hattori1, Oliver Schnell, Frank M Bengel, Julian Rihl, Stephan G Nekolla, Alexander E Drzezga, Eberhard Standl, Markus Schwaiger.   

Abstract

Effects of oxygen-derived free radicals are suggested to be a potential pathogenic factor for endothelial dysfunction. In this study we sought to evaluate the effect of hydroxyl radicals on the human coronary vascular bed in type I diabetes mellitus using positron emission tomography (PET). Thirteen patients with type 1 diabetes underwent PET using nitrogen-13 ammonia at rest and during sympathetic stimulation with the cold pressor test (CPT). The rest-stress study protocol was repeated twice (on different days) using pre-stress infusion of either saline as placebo or deferoxamine, an iron chelator which inhibits generation of hydroxyl radicals. At rest, global MBF was higher in diabetics than in normal controls (78.1+/-17.5 vs 63.2+/-14.9 mg 100 g(-1) min(-1), P<0.05) and myocardial vascular resistance (MVR) showed a trend towards lower values (patients, 1.28+/-0.35; controls, 1.55+/-0.32, P=NS). CPT increased MBF in all controls while 7/13 diabetics responded normally. CPT decreased MVR in 10/13 controls but in only 4/13 diabetics. There was no significant difference in the duration of diabetes, HbA1c, daily insulin dose, body mass index, or lipid profiles between patients with and patients without abnormal MBF or MVR responses. Pre-stress infusion of deferoxamine normalized MBF response in all six patients, and MVR response in six of the nine patients. Another group consisting of seven patients underwent a rest-rest protocol after infusion of deferoxamine and saline to investigate the effect of deferoxamine on resting MBF. Deferoxamine did not change the resting MBF (deferoxamine, 81+/-17 ml 100 g(-1) min(-1); saline, 75+/-19 ml 100 g(-1) min(-1), P=NS) or MVR (deferoxamine, 1.0+/-0.5 mmHg ml(-1) 100 g(-1) min(-1); saline, 1.2+/-0.6 mmHg ml(-1) 100 g(-1) min(-1), P=NS). In conclusion, inhibition of hydroxyl radical formation using deferoxamine significantly improved the responses of coronary microvasculature to sympathetic stimulation. Hydroxyl radicals may play a role in the pathogenesis of flow abnormalities in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111129     DOI: 10.1007/s00259-002-0799-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  5 in total

Review 1.  Role of PET in the evaluation and understanding of coronary physiology.

Authors:  Thomas H Schindler; Xiao-Li Zhang; Gabriella Vincenti; Leila Mhiri; René Lerch; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

Review 2.  Coronary vasomotor function assessed by positron emission tomography.

Authors:  Nagara Tamaki; Keiichiro Yoshinaga; Masanao Naya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-24       Impact factor: 9.236

3.  Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans.

Authors:  John O Prior; Thomas H Schindler; Alvaro D Facta; Miguel Hernandez-Pampaloni; Roxana Campisi; Magnus Dahlbom; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-11       Impact factor: 9.236

4.  Diabetes-induced changes in glucose synthesis, intracellular glutathione status and hydroxyl free radical generation in rabbit kidney-cortex tubules.

Authors:  K Winiarska; J Drozak; M Wegrzynowicz; T Fraczyk; J Bryla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

5.  Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with (13)N-ammonia and PET.

Authors:  Thomas H Schindler; Xiao-Li Zhang; John O Prior; Jerson Cadenas; Magnus Dahlbom; James Sayre; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.